Latest RNAi-siRNAI-miRNA-shRNA News

Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patentAlnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use...

Microorganism ID: Bacteria Identification Service by Altogen LabsAltogen Labs CRO, a preclinical contract research laboratory, announced its launch of microorganism ID bacteria identification service today. Microorganism identification and bioinformatic sequence characterization services are avail

Site-specific DICER and DROSHA RNA products control the DNA-damage responseNon-coding RNAs (ncRNAs) are involved in an increasingly recognized number of cellular events. Some ncRNAs are processed by DICER and DROSHA RNases to give rise to small double-stranded RNAs involved in RNA interference (RNAi). The DNA-damage respons...

AlCana Comments on Rulings Made in Civil SuitAlCana Technologies Inc. ("AlCana") commented today on recent rulings made in the civil suit brought by Tekmira Pharmaceuticals Inc. against certain current AlCana employees who were formerly employed by Tekmira ("former Tekmira employees"). On May 18, 2012, the Supreme Court of British Columbia denied Tekmira's application for injunctive relief and grante...

Variants in the 3′UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression

Cellectricon Launches Cellaxess® Elektra Discovery PlatformGOTHENBURG, Sweden, May 24, 2012 /PRNewswire/ -- Cellectricon is pleased to announce the new Cellaxess Elektra Discovery Platform which represents a revolutionary development in automated electric field manipulation of adherent cells. Developed in close collaboration with leading pharmaceutical and biotechnology companies, the platform is highly diverse and can be applied to a wide variety of cel...

Alnylam, PBL sign licensing agreement for Baulcombe & Hamilton RNAi patentAlnylam Pharmaceuticals and Plant Bioscience (PBL) have entered into a licensing agreement for Baulcombe & Hamilton RNAi patent.

Firefly Bags $500K from Massachusetts Life Science Center for miRNA Biomarker Platform

Alnylam secures rights to Plant Bioscience's RNAi patentPlant Bioscience granted Alnylam Pharmaceuticals global, non-exclusive licensing rights to the patent for Baulcombe and Hamil -More-

Oryzon Nominates Specific LSD1 Inhibitor as Drug Candidate to Enter Preclinical Development in Acute Leukemia and Other Hematological CancersOryzon announced today that it is entering preclinical development with its second drug candidate, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of hematological cancers. LSD1 inhibition reduced tumor load especially in acute leukemia models by targeting Leukemia Stem Cells, while normal myeloid progenitor cells were spared. Barcelona, Spain (PRWEB) May...

AMSBIO Announces a Fast Service for Custom Generation of High Quality, Affordable Over-expressing or Knockdown Stable Cell Lines (News)22 May 2012: Abingdon, UK - AMSBIO's custom generation of stable cell lines includes cloning the gene or shRNA of interest into a safe lentiviral vector, generating the lentivirus and transducing ...

Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi PatentAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Plant Bioscience Limited (PBL), a technology development and intellectual property (IP) management company, announced today that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license

LNA-based Oligonucleotide Electrotransfer for miRNA Inhibition

MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & SullivanLONDON, May 23, 2012 /PRNewswire/ -- A number of large pharmaceutical and biotech companies are keen to invest in life science research. Advances in genomic technologies and molecular biology segments will boost the microRNA (miRNA) research and tools market in the future. MicroRNA is set to unveil a new era in molecular diagnostics and in the development of effective therapeutics. New analy...

MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & SullivanLONDON, May 23, 2012 /- A number of large pharmaceutical and biotech companies are keen to invest in life science research. Advances in genomic technologies and molecular biology segments will boost the microRNA (miRNA) research and tools market...

MicroRNA research to trigger growth in related tools marketWidespread availability of miRNA research tools could reduce opportunities for services sector, says Frost & Sullivan

MicroRNAs as putative mediators of treatment response in prostate cancerMicroRNAs (miRNAs) have been implicated in prostate cancer initiation and progression, as well as response to cancer treatment. Here, O'Kelly and colleagues describe the basics of miRNA biology before discussing the available data on the role of miRN...

Arrowhead Presents Data on DPC System at TIDES 2012Arrowhead Research Corporation (NASDAQ:ARWR) today announced that Darren Wakefield, Ph.D., one of its Senior Scientists at its Madison, WI research and development facility presented data at the TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Conference in Las Vegas, NV. Dr. Wakefield’s poster presentation titled, “Liver...

Mirna Therapeutics Presents Updates on Development Program for Lead Therapeutic CandidateMirna Therapeutics, Inc., a biotechnology company pioneering microRNA replacement therapies for cancer, announced that new preclinical data from its lead therapeutic program will be presented this week at two different conferences: 2012 TIDES Oligonucleotide and Peptide Research, Technology, and Product Development Conference in Las Vegas, Nevada, and the...

Lundbeck and CHDI Foundation Announce Research Collaboration to Investigate Candidate Therapy for Huntington’s DiseaseCHDI Foundation, Inc. and Lundbeck today announced a research collaboration to investigate a targeted therapy for Huntington’s disease (HD). Currently, no treatment exists to slow or halt the progression of HD,1 a challenging hereditary neurodegenerative disease characterized by a triad of behavioral, cognitive, and motor symptoms.2 As part of t...

An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegenerationIn addition to their function in gene regulation, certain microRNAs can be secreted by cells. Here, the authors show that the microRNA let-7 can cause neurodegeneration by directly activating Toll-like receptor 7 and that individuals with Alzheimer's...

Marina Biotech and Girindus Group Announce Strategic Alliance CINCINNATI, OH and HANNOVER, GERMANY and BOTHELL, WA -- (Marketwire) -- 05/21/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, and Girindus Group today announced that they have entered into a strategic alliance where Girindus will have exclusive rights to develop, supply and commercialize certain oligonucleotide constructs using Marin...

Bioo Scientific Releases Improved Kits for Directed Drug DeliveryAustin, TX, May 18, 2012 --(PR.com)-- While it has been eleven years since the demonstration that sequence specific, small, synthetic, double stranded ribonucleic acids were shown to induce gene specific silencing in mammalian cells, delivery formulations that supply a metered dose of RNAi agent to the desired target site in a cost efficient fashion are still needed. Bioo Scientific has made adv...

Access Pharmaceuticals To Host Investor Call On Wednesday, May 23, 2012DALLAS and NEW YORK, May 17, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, will host an investor call to update investors on MuGard commercialization activities, including progress with pharmacy benefit managers, payers and...

New Data from Silence's Atu027 Anticancer Trial Published at ASCOLONDON, May 17, 2012 /PRNewswire/ -- - Atu027, a First in Class RNAi Therapy, Demonstrates Potential - Antitumour Activity in Cancer Patients and Possible Biomarker Identified Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNA...

0 1 2 3 4 ›»

buy RNAi-siRNAI-miRNA-shRNA market research data and corporate reports now Advertisement